Pancreatic hyperechogenicity associated with hypoadiponectinemia and insulin resistance: A Japanese population study

Table 3 Comparison of baseline characteristics between the pancreatic hyperechogenicity and control groups excluding participants with fatty liver

Clinical parameters	Pancreatic hyperechogenicity (n = 95)	Control (n = 171)	P value
Age (yr)	62 ± 9	58 ± 10	0.001
Sex (male/female)	44/51	76/95	0.769
Height (cm)	158.0 ± 8.0	158.1 ± 9.0	0.960
Weight (kg)	59.5 ± 9.4	53.9 ± 8.5	< 0.001
BMI (kg/m2)	23.7 ± 2.6	21.5 ± 2.5	< 0.001
Systolic BP (mmHg)	133 ± 17	130 ± 16	0.135
Diastolic BP (mmHg)	82 ± 11	80 ± 10	0.180
Adiponectin (μg/mL)	10.3 (7.6-14.6)	12.0 (8.6-17.0)	0.022
Serum insulin (μU/mL)	4.0 (2.7-5.4)	3.3 (2.5-4.5)	0.004
Fasting plasma glucose (mg/dL)	93 ± 8	90 ± 10	0.026
HOMA-IR	0.9 (0.59-1.28)	0.71 (0.54-1.02)	0.002
High-density lipoprotein cholesterol (mg/dL)	60 ± 15	66 ± 15	0.001
Low-density lipoprotein cholesterol (mg/dL)	124 ± 35	122 ± 33	0.708
Total cholesterol (mg/dL)	202 ± 33	199 ± 36	0.464
Triglyceride (mg/dL)	87 (66-133)	76 (59-96)	0.005
Pancreatic isoamylase (U/L)	29 (24-35)	31 (25-37)	0.054
Glutamic oxaloacetic transaminase (IU/L)	22 (19-25)	23 (19-28)	0.189
Glutamic pyruvic transaminase (IU/L)	19 (16-23)	20 (15-25)	0.937
γ-glutamyl transpeptidase (IU/L)	21 (16-40)	21 (15-32)	0.266
Preload plasma glucose (OGTT) (mg/dL)	96 ± 9	92 ± 10	0.009
2-h plasma glucose (OGTT) (mg/dL)	107 ± 29	100 ± 28	0.063

Data are expressed as means ± SD, or median (25^th; 75^th percentiles). Unpaired t test or Fisher’s exact test were used to compare the two groups. BMI: Body mass index; BP: Blood pressure; HOMA-IR: Homeostasis model assessment of insulin resistance; OGTT: Oral glucose tolerance test.